Related by context. All words. (Click for frequent words.) 76 Cloretazine 75 Cloretazine ® 75 alvespimycin 73 Cloretazine R 73 VNP#M 73 unique alkylating agent 72 galiximab 71 INCB# [001] 71 Phase Ib clinical 71 Panzem R NCD 71 neratinib 71 ganetespib 70 oral ridaforolimus 70 sapacitabine 70 ELACYT 70 Alocrest 70 obatoclax 70 phase IIa clinical 70 Phase Ib study 70 R#/MEM # 70 Dacogen injection 70 Phase Ib II 70 phase IIb clinical 70 elacytarabine 69 forodesine 69 OXi# 69 HGS ETR2 69 Triapine R 69 MGCD# [001] 69 phase Ib 69 Phase Ib 69 Onrigin 69 Phase IIIb clinical 69 BAY #-# 69 EOquin TM 69 refractory chronic lymphocytic 69 celgosivir 69 elotuzumab 69 Archexin 68 Tarceva TM 68 tanespimycin 68 IMA# 68 relapsed MM 68 relapsed refractory multiple myeloma 68 HER2 positive metastatic breast 68 pertuzumab 68 PXD# 68 rALLy clinical trial 68 radiation sensitizer 68 ara C 68 voreloxin 68 palifosfamide 68 PI3K/Akt pathway inhibitor 68 OvaRex R 68 glufosfamide 68 Androxal TM 68 Azedra TM 68 AP# [003] 68 Xanafide 68 oral talactoferrin 67 Phase III randomized controlled 67 relapsed multiple myeloma 67 Fludara 67 EndoTAG TM -1 67 Fibrillex TM 67 PDX pralatrexate 67 RhuDex ® 67 Amrubicin 67 Azedra 67 entinostat 67 oral prodrug 67 Panzem R 67 Triapine 67 rNAPc2 67 phase IIa 67 HGS# 67 TELCYTA 67 YONDELIS 67 aflibercept VEGF Trap 67 BrachySil TM 67 MAGE A3 ASCI 67 Phase #b/#a trial 67 BRIM2 67 receptor tyrosine kinase inhibitor 67 sorafenib Nexavar ® 67 AEG# 67 Bezielle 67 Phase #b/#a 67 Tyrima 67 CA4P 67 enzastaurin 67 romidepsin 67 KRN# 67 Romidepsin 67 pharmacokinetic PK study 67 Fx #A 67 mertansine 67 MOZOBIL 67 dacetuzumab 67 Phase 1b clinical 67 pomalidomide 67 Phase 1b trial 66 Targretin capsules 66 UVIDEM 66 PEG SN# 66 Traficet EN 66 trastuzumab Herceptin R 66 HGS ETR1 66 Aplidin 66 TBC# 66 evaluating tivozanib 66 sunitinib malate 66 Elotuzumab 66 fosbretabulin 66 evaluating Xcytrin 66 oral picoplatin 66 OvaRex ® MAb 66 TLK# 66 axitinib 66 deforolimus 66 Phase #b/#a clinical 66 ularitide 66 XL# XL# 66 PSMA ADC 66 BCX# 66 huN# DM1 66 erlotinib Tarceva ® 66 relapsed acute myelogenous 66 HuMax EGFr 66 Proxinium TM 66 nab paclitaxel 66 Virulizin ® 66 HQK 66 vidofludimus 66 Anturol TM 66 riociguat 66 vosaroxin 66 adecatumumab 66 metaglidasen 66 Phase 2a clinical 66 SNT MC# 66 selective androgen receptor modulator 66 triphendiol 66 CEQ# 66 Ophena TM 66 melphalan prednisone 66 Phase IIb clinical trials 66 ZYBRESTAT 66 Bortezomib 66 sargramostim 66 metastatic HRPC 66 Golimumab 66 bortezomib Velcade R 66 NOX E# 66 MGd 66 lintuzumab 66 torezolid phosphate 66 VELCADE melphalan 66 TKM ApoB 66 EOquin 66 confirmatory Phase III 66 rALLy 66 leukemia AML 66 ATL# [001] 66 Phase IIa trials 66 Phase 2a trial 66 OncoVEX GM CSF 66 Sym# 66 Phase 1b 66 sorafenib Nexavar 66 dose escalation trial 66 PEG PAL 66 Perifosine 66 Voreloxin 66 CLARITY study 66 paclitaxel Taxol ® 66 histamine dihydrochloride 65 Neuradiab 65 docetaxel Taxotere R 65 LEP ETU 65 Phase 1a clinical 65 registrational trial 65 perifosine 65 ascending dose 65 TELINTRA 65 IIa trial 65 Hsp# Inhibitor 65 ofatumumab 65 CALGB # [002] 65 aflibercept 65 CCX# 65 Aflibercept 65 Pivotal Phase III 65 Azedra ™ 65 lintuzumab SGN 65 GRN# 65 Enzastaurin 65 Chemophase 65 Gemzar ® 65 PRT# 65 apoptosis inducer 65 lenalidomide Revlimid R 65 AQ4N 65 eculizumab 65 generation Hsp# inhibitor 65 urocortin 2 65 teriflunomide 65 TRO# 65 novel histone deacetylase 65 metastatic hormone refractory 65 Seliciclib 65 phase 2a 65 Troxatyl 65 liposomal formulation 65 Phase 2b study 65 GSK# [001] 65 GAMMAGARD 65 relapsed AML 65 assessing T DM1 65 nalbuphine ER 65 recurrent glioblastoma multiforme 65 DOXIL 65 CYT# potent vascular disrupting 65 LymphoStat B belimumab 65 Zemplar Capsules 65 phase IIb III 65 ancrod 65 Phase 2a 65 Phase 2b trial 65 mRCC 65 dexanabinol 65 dasatinib Sprycel ® 65 Phase IIb III 65 azacitidine 65 randomized Phase IIb 65 Onconase 65 CR# vcMMAE 65 EndoTAGTM 1 65 vinorelbine 65 pralatrexate 65 docetaxel chemotherapy 65 CTAP# Capsules 65 antibody MAb 65 rALLy trial 65 hormone LHRH antagonist 65 Phase IIa 65 Omacetaxine 65 dose escalation clinical 65 ORENCIA ® 65 Phase IIB 65 phase IIb study 65 CRLX# 65 Cloretazine VNP#M 65 PSN# [002] 65 Phase III clinical 65 placebo controlled Phase III 65 relapsed myeloma 65 Proellex TM 65 oxymorphone ER 65 REOLYSIN ® 65 refractory acute myeloid 65 TRISENOX 65 ZOLINZA 65 miconazole Lauriad ® 65 GMX# 65 Factor VIIa 65 octreotide implant 65 zanolimumab 65 Tanespimycin 65 Genasense ® 65 vinorelbine tartrate 65 maximally tolerated dose 65 Onrigin TM 64 Solazed 64 VEGF Trap 64 KNS # 64 docetaxel Taxotere 64 lomitapide 64 brentuximab vedotin SGN 64 PNP inhibitor 64 IL# PE#QQR 64 PLK1 SNALP 64 Annamycin 64 Zenvia TM 64 Pemetrexed 64 cilengitide 64 diabetic neuropathic pain 64 pan HDAC inhibitor 64 ZYBRESTAT fosbretabulin 64 GW# [003] 64 ISTODAX 64 PDE4 inhibitor 64 CoFactor 64 amrubicin 64 OMP #M# 64 Phase Ia 64 MAP# 64 platinum refractory 64 IRX 2 64 Virulizin R 64 Matrix Phase 2b 64 dosing cohort 64 SinuNase TM 64 tolevamer 64 mapatumumab 64 acetonide FA 64 Clolar ® 64 thalidomide Thalomid 64 2 methoxyestradiol 64 Vidaza azacitidine 64 acyclovir Lauriad R 64 systemic anaplastic large 64 IMGN# 64 JAK inhibitor 64 RGB # 64 anticancer compound 64 lorvotuzumab mertansine 64 incyclinide 64 XP# XP# 64 investigational monoclonal antibody 64 ATL/TV# 64 CLORETAZINE TM VNP#M 64 CIMZIA TM 64 ISIS # 64 tezampanel 64 generation purine nucleoside 64 custirsen 64 eosinophilic asthma 64 HCD# [002] 64 EVIZON TM squalamine lactate 64 Marqibo 64 CRMD# 64 small molecule chemotherapeutic 64 docetaxel Taxotere ® 64 IMC A# 64 DDP# 64 thymalfasin 64 torsemide ER 64 APEX PD 64 Phase 2b clinical 64 trastuzumab DM1 T DM1 64 refractory AML 64 MYCAMINE 64 dose escalation Phase 64 omacetaxine mepesuccinate 64 Dyloject TM 64 Phenoptin 64 cell lymphoma CTCL 64 huC# DM4 64 dextromethorphan quinidine 64 HuMax CD4 64 veltuzumab 64 cediranib 64 UPLYSO 64 histone deacetylase HDAC inhibitor 64 anti leukemic 64 XL# SAR# 64 carboplatin paclitaxel 64 Aplidin R 64 Altastaph 64 ongoing Phase 1b 64 orally administered inhibitor 64 capecitabine Xeloda R 64 Specifid 64 placebo controlled Phase 64 L BLP# 64 novel VDA molecule 64 NXL# 64 AKT inhibitor 64 metastatic castration resistant 64 vascular disrupting agent 64 AzaSite Plus 64 Elagolix 64 XL# XL# XL# XL# 64 LE DT 64 decitabine 64 ixabepilone 64 FOLOTYN ® 64 low dose cytarabine 64 OMP #R# 64 novel anticancer 64 Phase 1b clinical trials 64 Alzhemed TM 64 Ceflatonin 64 CCX# B 64 Exherin TM 64 SILENOR TM 64 heavily pretreated 64 oral rivaroxaban 64 phase IIb 64 CIMZIA TM certolizumab pegol 64 registrational 64 ORENCIA R 64 BrachySil 64 paclitaxel poliglumex 64 intravenous belinostat 64 Spiegelmer ® 64 Bicifadine 64 SUCCEED trial 64 AMD# [003] 64 DermaVir Patch 64 TMC# [002] 64 CCR9 antagonist 64 Phase IIa clinical 64 Exelixis compounds 64 refractory metastatic colorectal cancer 64 gemcitabine cisplatin 64 ON #.Na 63 Aurexis 63 cariprazine 63 DXL# 63 lumiliximab 63 eltrombopag 63 baminercept 63 PRTX 63 TASKi2 63 oxidative stress inducer 63 orally bioavailable 63 ruxolitinib 63 Mipomersen 63 CBLC# 63 TH# [003] 63 Pertuzumab 63 ThermoDox R 63 MEK inhibitor 63 AEGR 63 OMNARIS HFA 63 randomized Phase 2b 63 tubulin inhibitor 63 CIMZIA ™ 63 PEGPH# 63 ONCONASE R 63 dose escalation 63 TG# [001] 63 Phase 1a 63 multicenter Phase II 63 GRN#L 63 talactoferrin 63 MAXY alpha 63 standard chemotherapy regimen 63 Initiated Phase 63 potent triglyceride lowering 63 remission induction 63 MGCD# [002] 63 SPRYCEL ® 63 Omnitarg 63 Meets Primary Endpoint 63 Ozarelix 63 3 registrational trial 63 ZK EPO 63 bevacizumab Avastin 63 teduglutide 63 MoxDuo IR 63 AeroLEF TM 63 omecamtiv mecarbil 63 tesmilifene 63 CANCIDAS 63 Phase Ib IIa 63 targeted radiotherapeutic 63 multicenter randomized placebo controlled 63 malignant ascites 63 EP #R 63 Glufosfamide 63 nonclinical studies 63 volociximab 63 tramiprosate Alzhemed TM 63 Bayer HealthCare Onyx Pharmaceuticals 63 StemEx 63 imetelstat 63 Phase III 63 Carfilzomib 63 Aryplase 63 dose cohort 63 IMC #B 63 OHR/AVR# 63 GRNVAC1 63 thetreatment 63 refractory indolent non 63 tolerated dose MTD 63 Cimzia TM 63 MEND CABG II 63 bortezomib Velcade 63 Phase Ib clinical trials 63 Dasatinib 63 Pharmacokinetics PK 63 Soliris TM eculizumab 63 relapsed ALL 63 evaluating satraplatin 63 Vicinium TM 63 pharmacodynamic PD 63 preclinical efficacy 63 Personalized Immunotherapy 63 oral antiviral 63 including eniluracil ADH 63 evaluating picoplatin 63 CB2 selective receptor agonist 63 metastatic castrate resistant 63 Vion Pharmaceuticals 63 dose escalation phase 63 Dalbavancin 63 bevacizumab Avastin ® 63 tosedostat 63 treatment naive genotype 63 OMS# 63 immunotherapeutic agent 63 Zerenex 63 Panzem NCD 63 Aclidinium 63 Velcade bortezomib 63 ONCONASE 63 Natalizumab 63 picoplatin 63 delivers fluocinolone acetonide FA 63 Neurodex 63 trabectedin 63 refractory Hodgkin lymphoma 63 PANVAC VF 63 cutaneous T 63 RLY# 63 cutaneous T cell 63 bicifadine 63 Blinatumomab 63 FOLOTYN 63 ILUVIEN ® 63 EmbraceAC 63 depsipeptide 63 bendamustine 63 leading oral taxane 63 farletuzumab 63 proteasome inhibitor bortezomib 63 Plicera 63 TG# [003] 63 vinca alkaloid 63 herpetic keratitis 63 opioid induced bowel dysfunction 63 Iluvien TM 63 Zenvia ™ 63 Stedivaze 63 Trofex 63 forodesine hydrochloride 63 Ceflatonin R 63 reslizumab 63 BRIM3 63 regorafenib 63 Fludarabine 63 GALNS 63 rindopepimut 63 RhuDex TM 63 JAK2 inhibitor 63 Vitaxin 63 CD# CEA 63 demonstrated antitumor activity 63 Xeloda ® 63 Prodarsan ® 63 XL# [003] 63 NP2 Enkephalin 63 sorafenib tablets 63 phase IIb trial 63 dirucotide MBP# 63 Zemiva ™ 63 stated Michelle Berrey 63 estramustine 63 Novolimus 63 refractory gout 63 Ibritumomab Tiuxetan 63 samalizumab 63 TASKi3 63 TTF Therapy 63 Metastatic Melanoma 63 combretastatin A4 phosphate CA4P 63 Darusentan 63 Neulasta ® 63 mitogen activated ERK kinase 63 HDAC Inhibitor 63 PS# [001] 63 Xelox 63 somatostatin analogue 63 refractory colorectal cancer 63 oxypurinol 63 Dacogen decitabine 63 atacicept 63 Trofex TM 63 HRPC 63 HuLuc# 63 BLP# Liposome Vaccine 63 severe hypercholesterolemia 62 Taxotere ® 62 HoFH 62 GLPG# 62 Onalta ™ 62 oral anticancer 62 NGX# 62 recurrent herpes labialis 62 abiraterone acetate 62 Zerenex ™ 62 intranasal formulation 62 PEG Interferon lambda 62 Hyphanox 62 sitaxsentan 62 TREANDA 62 velafermin belinostat 62 dirucotide 62 refractory multiple myeloma 62 Anturol ® 62 budesonide foam 62 Asentar 62 ZACTIMA 62 alfa 2a 62 phase IIIb 62 cannabinor 62 EFAPROXYN 62 EDEMA3 trial 62 hoFH 62 IV Busulfex 62 Marqibo TM 62 uric acid lowering 62 Erlotinib 62 tumor vascular disrupting 62 Lenocta 62 BEMA TM Fentanyl 62 indibulin 62 plus prednisone prednisolone 62 GetGoal Phase III 62 GATTEX TM 62 subcutaneous formulation 62 bardoxolone 62 Luteinizing Hormone Releasing Hormone 62 Saforis 62 nucleoside analog 62 GEM OS2 62 clofarabine 62 colesevelam HCl 62 CYT# 62 MAXY G# 62 Allovectin 7 R 62 Initiate Phase 62 Aloxi injection 62 catheter occlusion 62 Topical Interferon Alpha 2b 62 Phase IIb 62 Myocet 62 refractory CTCL 62 Phase #/#a trial 62 temsirolimus 62 randomized controlled Phase 62 Forodesine HCl 62 Immunotherapeutic 62 Clofarabine 62 tamibarotene 62 alemtuzumab Campath 62 carfilzomib 62 phase III isavuconazole 62 mGluR5 NAM 62 Randomized Phase 62 ceftazidime 62 BEXXAR 62 Excellarate 62 sapacitabine CYC# 62 PROSTVAC VF 62 INCB# [003] 62 Imprime PGG 62 recurrent NSCLC 62 systemic ALCL 62 Ixempra 62 advanced carcinoid 62 relapsed SCLC 62 BR.# 62 Phase IIa trial 62 Inhalation Solution 62 talabostat 62 Eculizumab 62 Pyridorin 62 ProLindac 62 CINQUIL 62 Cleviprex TM clevidipine 62 OvaRex 62 Maribavir 62 Evoltra ® 62 targeted antifolate 62 R lenalidomide 62 Tectin TM 62 tezampanel NGX# 62 Phase 2b Clinical Trial 62 erythropoietic 62 LE SN# 62 multicenter Phase 62 Phase 2b 62 Revlimid lenalidomide 62 MyVax R 62 Genasense ® oblimersen 62 Cannabinor 62 Symadex 62 placebo controlled clinical 62 OPAXIO 62 vascular disrupting agents 62 Tezampanel 62 Sapacitabine 62 RH1 62 KIACTA ™ 62 Nanobody 62 castrate resistant prostate cancer 62 AAG geldanamycin analog 62 adalimumab Humira 62 USL# 62 weekly subcutaneous injections 62 GLP toxicology studies 62 boosted protease inhibitor 62 multiple myeloma MM 62 Solazed TM 62 DCCR 62 Junovan 62 hA# 62 elesclomol 62 non nucleoside inhibitor 62 Neupogen ® 62 HspE7 62 gemcitabine Gemzar ® 62 Tesetaxel 62 Hedgehog Pathway Inhibitor 62 ADVANCE PD 62 FOLFOX6 chemotherapy regimen 62 oral deforolimus 62 ARIKACE ™ 62 Vicriviroc 62 Combidex 62 relapsing multiple sclerosis 62 Tasimelteon 62 nucleoside reverse transcriptase inhibitor 62 Zybrestat 62 Bendamustine 62 ApoB SNALP 62 ALS #-# 62 gemcitabine carboplatin 62 ISTODAX ® 62 ATL# [002] 62 RDEA# 62 Gabapentin GR 62 certolizumab 62 proteasome inhibitor 62 masked placebo controlled 62 Tarvacin TM 62 lexidronam injection 62 dose cohorts 62 Phase III Pivotal 62 romidepsin novel 62 Genasense R oblimersen 62 IIb clinical trial 62 blinded randomized placebo controlled 62 refractory CLL 62 ENMD # 62 Pralatrexate 62 Capesaris 62 Triolex 62 cancer neuroendocrine tumor 62 TOCOSOL Paclitaxel 62 pivotal Phase III 62 Clonicel 62 alvimopan 62 salmeterol fluticasone 62 irinotecan doxorubicin oxaliplatin paclitaxel 62 dextofisopam 62 Cutaneous T 62 cangrelor 62 NEUMUNE 62 EGFr expressing metastatic colorectal 62 Granulocyte Colony Stimulating Factor 62 metastatic renal cell carcinoma 62 LEUKINE 62 CA9 SCAN 62 PGL# 62 dasatinib Sprycel 62 GATTEX ™ 62 PTH analogue 62 cytarabine 62 CHOP chemotherapy 62 Telintra 62 eniluracil 62 APOPTONE 62 brivaracetam 62 Medidur TM FA 62 Vidaza ® 62 ® bortezomib 62 oral methylnaltrexone 62 JVRS 62 ASONEP 62 diarrhea predominant irritable 62 octreotide acetate 62 PROVENGE sipuleucel T 62 antimetabolite 62 relapsed CLL 62 therapeutic monoclonal antibody 62 CHARM Added 62 pharmacokinetic PK 62 antiangiogenic agent 62 vernakalant hydrochloride 62 inhaled treprostinil 62 Acute Myeloid Leukemia 62 Doxil ® 62 XYOTAX TM 62 PrevOnco 62 ofatumumab HuMax CD# 62 pharmacodynamics PD 62 ARIKACE 62 telomerase therapeutic 62 rilonacept 62 dopamine partial agonist 62 PEGylated interferon beta 1a 62 PEGylated interferon 62 Xcellerated T Cells 62 Epratuzumab 62 midstage clinical 62 cisplatin gemcitabine 62 LymphoStat B TM 62 investigational humanized monoclonal antibody 62 IAP inhibitors 62 SYN# 62 severe gastroparesis 62 phase III ACCLAIM 62 iobenguane 62 favorable pharmacokinetic profile 62 prostate cancer HRPC 61 Ceflatonin ® 61 metastatic malignant 61 multiple ascending dose 61 pegfilgrastim 61 tipranavir r 61 Aeroquin 61 chemotherapy induced neutropenia 61 Abiraterone acetate 61 pegylated liposomal doxorubicin 61 REGN# 61 5 fluorouracil leucovorin 61 ritonavir boosted protease inhibitor 61 BRAF inhibitor 61 IFN α 61 DEB# 61 PHX# 61 Copegus ribavirin 61 Oral NKTR 61 TACI Ig 61 ZYBRESTAT TM 61 trial evaluating Prochymal 61 ocular formulation 61 Ceplene/IL-2 61 seliciclib CYC# 61 oral beclomethasone dipropionate 61 pharmacodynamic properties 61 Azixa 61 Microplasmin 61 IMPDH inhibitor 61 tigecycline 61 MKC# PP 61 lapatinib Tykerb 61 Mitoxantrone 61 XOMA 3AB 61 hypoxia selective 61 Apoptone 61 Degarelix 61 Ocrelizumab 61 Daclizumab 61 gemtuzumab ozogamicin 61 randomized multicenter Phase III 61 danoprevir 61 Allovectin 7 61 EGS# 61 dacarbazine DTIC 61 oblimersen 61 PSN# [001] 61 abatacept Orencia 61 evaluating MGCD# [002] 61 PROMACTA 61 Peginterferon alfa 2b 61 trastuzumab Herceptin 61 PEP# [003] 61 ONTAK 61 TASQ 61 Phase III psoriasis 61 Urocidin TM 61 IMPACT DCM clinical 61 ALN PCS 61 Teriflunomide 61 polymerase inhibitor 61 Prodarsan 61 RAPTIVA 61 pamidronate 61 corticosteroid dexamethasone 61 Targretin 61 velafermin 61 immunomodulatory therapy 61 ascending doses 61 Dapagliflozin 61 Zolinza 61 AVN# [001] 61 non metastatic osteosarcoma 61 lesinurad 61 idarubicin 61 bevacizumab Avastin R 61 MYDICAR ® 61 untreated multiple myeloma 61 PKC# 61 XL# anticancer compounds 61 confirmatory clinical 61 CLL SLL 61 OncoVEX 61 Peginterferon 61 PF # [002] 61 DAVANAT 61 refractory cutaneous T 61 IMiDs R 61 LUMINATE 61 Phase IIb clinical 61 CAELYX 61 TRISENOX ® 61 pharmacokinetics PK 61 inhaled AAT 61 NVA# 61 ThermoDox ® clinical 61 alkylating agent 61 IAP inhibitor 61 comparator arm 61 Initiate Clinical Trial 61 fluoropyrimidine 61 Hepatocellular Carcinoma HCC 61 novel oral anticoagulant 61 Folfox 61 G#DT 61 Elocalcitol 61 Phase II 61 TORISEL 61 RG# [001] 61 registrational Phase 61 MDS AML 61 ACAPODENE 61 seliciclib 61 Octreolin 61 PREOS 61 MEK inhibitor RDEA# 61 davunetide intranasal AL 61 ataluren 61 hormone refractory metastatic prostate 61 Ophena 61 taxane resistant 61 tesetaxel 61 5 FU leucovorin 61 multicenter placebo controlled 61 HGS ETR1 mapatumumab 61 overactive bladder AA# 61 TO AVOID PREGNANCY WHILE 61 generation NNRTI 61 CCR5 antagonist 61 Allovectin 7 ® 61 peritumoral brain edema 61 immune modulating 61 GATTEX ® 61 oral FTY# 61 concurrent chemoradiation 61 REVLIMID lenalidomide 61 evaluating T DM1 61 Quinamed 61 PEG IFN 61 DASISION 61 xanthine oxidase inhibitor 61 azilsartan medoxomil 61 XL# XL# XL# 61 Pivotal Phase 61 ELND# 61 liposomal doxorubicin 61 blinatumomab 61 subcutaneous PRO 61 Parathyroid Hormone 61 PEGylated Fab fragment 61 RSD# oral 61 telaprevir VX 61 double blinded placebo 61 Lenocta TM 61 Prospective Randomized 61 TKB# 61 Melphalan 61 pharmacodynamic parameters 61 ASA# 61 Phase III VISTA 61 Darinaparsin 61 afatinib 61 alpha 2a 61 MKC# MT 61 Cimzia ® certolizumab pegol 61 immune modulatory 61 pseudobulbar affect PBA 61 Teysuno 61 radiotherapeutic 61 satraplatin Phase 61 Anturol 61 PREOS R 61 #I TM# 61 L Annamycin 61 tolerability 61 taxane refractory 61 Phase IIb trials 61 dimebon latrepirdine